About this episode
Drs. Karl and Spencer discuss the topline results from Surmount 5 which put Zepbound (tirzepatide) against Wegovy (semaglutide) for weight loss. They also discuss some news around compounded GLP-1s.
Learn:
Weight loss and glycemic differences between tirzepatide and semaglutide
What the FDA is thinking for compounded GLP-1s
If you're not on Dr. Spencer's virtual clinic waitlist, click here
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Get every episode summarized
Each time Docs Who Lift publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Docs Who Lift
Does Metabolically Healthy Obesity Even Exist?
Docs Who Lift
Is Your Obesity Genetic? Food Noise and Bardet-Biedl Syndrome Explained
Docs Who Lift
PCOS Renamed to PMOS? Here's Why and What Changes for You
Docs Who Lift
Are Peptides the New Snake Oil? What the Actual Science Says With Barbell Medici...
Docs Who Lift